Success Metrics

Clinical Success Rate
78.4%

Based on 58 completed trials

Completion Rate
78%(58/74)
Active Trials
6(6%)
Results Posted
36%(21 trials)
Terminated
16(17%)

Phase Distribution

Ph phase_1
36
38%
Ph phase_2
28
30%
Ph early_phase_1
4
4%
Ph phase_4
8
9%
Ph not_applicable
5
5%
Ph phase_3
6
6%

Phase Distribution

40

Early Stage

28

Mid Stage

14

Late Stage

Phase Distribution87 total trials
Early Phase 1First-in-human
4(4.6%)
Phase 1Safety & dosage
36(41.4%)
Phase 2Efficacy & side effects
28(32.2%)
Phase 3Large-scale testing
6(6.9%)
Phase 4Post-market surveillance
8(9.2%)
N/ANon-phased studies
5(5.7%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

75.3%

58 of 77 finished

Non-Completion Rate

24.7%

19 ended early

Currently Active

6

trials recruiting

Total Trials

94

all time

Status Distribution
Active(6)
Completed(58)
Terminated(19)
Other(11)

Detailed Status

Completed58
Terminated16
unknown11
Recruiting4
Withdrawn3
Active, not recruiting2

Development Timeline

Analytics

Development Status

Total Trials
94
Active
6
Success Rate
78.4%
Most Advanced
Phase 4

Trials by Phase

Early Phase 14 (4.6%)
Phase 136 (41.4%)
Phase 228 (32.2%)
Phase 36 (6.9%)
Phase 48 (9.2%)
N/A5 (5.7%)

Trials by Status

recruiting44%
terminated1617%
unknown1112%
active_not_recruiting22%
completed5862%
withdrawn33%

Recent Activity

Clinical Trials (94)

Showing 20 of 94 trialsScroll for more
NCT01552434Phase 1

Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease

Active Not Recruiting
NCT05821556Phase 2

Valproic Acid/Simvastatin Plus Gemcitabine/Nab-paclitaxel Based Regimens in Untreated Metastatic Pancreatic Adenocarcinoma Patients

Recruiting
NCT02068586Phase 2

Sunitinib Malate or Valproic Acid in Preventing Metastasis in Patients With High-Risk Uveal Melanoma

Active Not Recruiting
NCT06729970Phase 1

A Study to Evaluate the Effects of Lithium, Valproic Acid, and Lamotrigine on the Pharmacokinetics of KarXT and Effects of KarXT on the Pharmacokinetics of Lithium, Valproic Acid, and Lamotrigine in Healthy Participants

Completed
NCT03196466

Population Pharmacokinetics of Antiepileptic in Pediatrics

Completed
NCT07052136Not Applicable

Efficacy Comparison Between Levetiracetam and Valproic Acid in Pediatric Patients With Status Epilepticus

Completed
NCT06199557Phase 1

A Study to Investigate Treatment of HU and VPA, or 6-MP and VPA in Unfit AML/HR-MDS Patients

Recruiting
NCT03357757Phase 2

Avelumab With Valproic Acid in Virus-associated Cancer

Completed
NCT03048084Phase 4

Seizure Treatment in Glioma

Recruiting
NCT06674070

SCN2A Polymorphisms Are Associated With Response to Valproic Acid in Paediatric Population(Pakistan)

Completed
NCT01817751Phase 2

Sorafenib, Valproic Acid, and Sildenafil in Treating Patients With Recurrent High-Grade Glioma

Completed
NCT06248931Phase 3

Valproate Versus Topiramate in Migraine

Completed
NCT02893371

Longitudinal Comparative Effectiveness of Bipolar Disorder Therapies

Terminated
NCT04310176Phase 2

Valproic Acid in Combination With Bevacizumab and Oxaliplatin/Fluoropyrimidine Regimens in Patients With Ras-mutated Metastatic Colorectal Cancer

Unknown
NCT02624128Phase 2

Valproic Acid Plus Cisplatin and Cetuximab in Recurrent and/or Metastatic Squamous Cell Carcinoma of Head and Neck

Unknown
NCT00374075Phase 1

Study of Safety and Dosing Effect on SMN Levels of Valproic Acid (VPA) in Patients With Spinal Muscular Atrophy

Completed
NCT01898104Phase 1

Preoperative Valproic Acid and Radiation Therapy for Rectal Cancer

Unknown
NCT00289952Phase 2

Valproic Acid and Its Effects on HIV Latent Reservoirs

Completed
NCT05697614Phase 4

The Benefit and Safety of Older Generation Anti-Epileptic Drugs (AEDs) in Drug-Resistant Epilepsy Children

Unknown
NCT04531592Phase 2

Valproic Acid (VPA) for Acute Kidney Injury (AKI) in Liver Transplant Patients

Withdrawn

Drug Details

Intervention Type
DRUG
Total Trials
94